Two patients who developed refractory sclerodermatous cGVHD following allo-SCT received imatinib mesylate at the dose of 400 mg/day. In both patients, the scleroderma symptoms disappeared within ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback